Cargando…

Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients

New treatments based on combinations of standard therapeutic modalities and immunotherapy are of potential use, but require a profound understanding of immune modulatory properties of standard therapies. Here, the impact of standard (chemo)radiotherapy on the immune system of cervical cancer patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Meir, H., Nout, R. A., Welters, M. J. P., Loof, N. M., de Kam, M. L., van Ham, J. J., Samuels, S., Kenter, G. G., Cohen, A. F., Melief, C. J. M., Burggraaf, J., van Poelgeest, M. I. E., van der Burg, S. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353924/ https://www.ncbi.nlm.nih.gov/pubmed/28344877 http://dx.doi.org/10.1080/2162402X.2016.1267095

Ejemplares similares

Synergy of therapeutic vaccination against HPV16 oncogenic proteins and standard chemotherapeutics
por: Melief, Cornelis J, et al.
Publicado: (2014)

A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions
por: de Vos van Steenwijk, Peggy J., et al.
Publicado: (2012)

Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer
por: Talebian Yazdi, Mehrdad, et al.
Publicado: (2016)

TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients
por: Zom, Gijs G., et al.
Publicado: (2016)

Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer
por: van Poelgeest, Mariëtte I. E., et al.
Publicado: (2016)

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
por: van Poelgeest, Mariette I E, et al.
Publicado: (2013)

PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System
por: Corbeau, Anouk, et al.
Publicado: (2021)

Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions
por: Speetjens, Frank M, et al.
Publicado: (2022)

Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?
por: Melief, Cornelis J.M.
Publicado: (2022)

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer
por: Dijkgraaf, Eveline M., et al.
Publicado: (2015)

CD163(+) cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer
por: Santegoets, Saskia J, et al.
Publicado: (2020)

Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination
por: Abdulrahman, Ziena, et al.
Publicado: (2020)

Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1 T cell responses
por: Santegoets, S. J., et al.
Publicado: (2019)

Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer
por: Moelans, Cathy B., et al.
Publicado: (2018)

Synergy between chemotherapy and cancer vaccination
por: van der Sluis, Tetje C., et al.
Publicado: (2015)

CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors
por: Duurland, Chantal L, et al.
Publicado: (2022)

Monitoring of the Immune Dysfunction in Cancer Patients
por: Santegoets, Saskia J. A. M., et al.
Publicado: (2016)

Successful treatment of primary cutaneous angiosarcoma of the nose with sequential chemo- and radiotherapy
por: Herrscher, H., et al.
Publicado: (2019)

Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma
por: Talebian Yazdi, Mehrdad, et al.
Publicado: (2015)

Mobile e‐diary application facilitates the monitoring of patient‐reported outcomes and a high treatment adherence for clinical trials in dermatology
por: Rijsbergen, M., et al.
Publicado: (2019)

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival
por: Santegoets, S. J. A. M., et al.
Publicado: (2018)

Implementation of state-of-the-art (chemo)radiation for advanced cervix cancer in the Netherlands: A quality improvement program
por: De Leeuw, Astrid A.C., et al.
Publicado: (2018)

The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools
por: Singh, Satwinder Kaur, et al.
Publicado: (2012)

Early body weight loss during concurrent chemo-radiotherapy for non-small cell lung cancer
por: Op den Kamp, Céline M. H., et al.
Publicado: (2014)

Antibodies against p53 are associated with poor prognosis of colorectal cancer.
por: Houbiers, J. G., et al.
Publicado: (1995)

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
por: Venneker, Sanne, et al.
Publicado: (2019)

Concurrent chemo-radiotherapy with proton therapy: reduced toxicity with comparable oncological outcomes vs photon chemo-radiotherapy
por: Baumann, Brian C., et al.
Publicado: (2020)

The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization
por: Koskimaa, H.-M., et al.
Publicado: (2017)

A Comparison Between Chemo-Radiotherapy Combined With Immunotherapy and Chemo-Radiotherapy Alone for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Lara-Velazquez, Montserrat, et al.
Publicado: (2021)

The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma
por: Welters, Marij J. P., et al.
Publicado: (2020)

Role of IL-12p40 in cervical carcinoma
por: Zijlmans, H J M A A, et al.
Publicado: (2012)

Laparoscopic salvage total pelvic exenteration: Is it possible post-chemo-radiotherapy?
por: Patel, H, et al.
Publicado: (2009)

Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative
por: Koskimaa, Hanna-Mari, et al.
Publicado: (2015)

Fertility preservation in chemo-radiotherapy for rectal cancer: A combined approach
por: Mariani, S., et al.
Publicado: (2019)

Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis
por: Ma, Wenbo, et al.
Publicado: (2016)

High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status
por: Kortekaas, Kim E., et al.
Publicado: (2019)

Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers
por: Deist, Timo M., et al.
Publicado: (2018)

IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma
por: Melief, Sara M., et al.
Publicado: (2017)

The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival
por: Santegoets, Saskia J., et al.
Publicado: (2023)

Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program
por: Mander, A., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_shabpa9o642r3hikfs5s7hib32